SAGIMET BIOSCIENCES, Inc

Senior Vice President of CLINICAL operations: Katharine Grimmer

Katharine brings 25+ years of experience developing novel therapies. She has led Sagimet’s Clinical Operations team since 2014 through several multinational studies. Katharine started her career at Genentech working on anti-Her2 compounds, Perjeta and Kadcyla.

Since then she has taken positions of increasing responsibility primarily in the areas of oncology and metabolic disease. Her experience spans first in human to Phase 3 registrational studies. At Genentech, she led the early trials for BCC (Erivedge), GBM (Avastin) and Ovarian Cancer (Avastin).

As a former caregiver, Katharine is a patient advocate and has a passion for developing lifesaving therapies in areas of unmet need. Her greatest achievement to date was contributing to the development of two drugs that extended her mother’s battle with cancer by at least 10 years. Her volunteer work is with SecondOpinion.org and SF Koman. She holds a Biology degree from UC Davis and an executive MBA from USF.